The datasets (GSE62646 and GSE59867), including stable CAD and STEMI patients, were used for further validations, an important risk factor for obstructive CAD.22, 23, 24 By doing this, the current study demonstrates that either gene, including NCF2, MYO1F, S1PR4, and FCN1, combined with the risk factors (including gender and hyperlipidemia), in PBMCs, was identified as a novel biomarker for obstructive CAD. Here, MYO1F is linked to hyperlipidemia.